Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Outline of Final Research Achievements |
CD271 is a candidate cancer stem cell marker for HNSCC, but its functional role is left undetermined. By a co-purificaton approach, we identified Cortactin as a binding partner. CD271 positive cells expressed Cortactin, and cortactin-low cells showed decreased tumorigenesis and motility, which is similar to the CD271-loss phenotypes. Notably, actin network was damaged in cortactin-low cells. These results suggest CD271 and cortactin are potential therapeutic targets of head and neck cancer.
|